A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma.
J Exp Med
; 183(6): 2501-8, 1996 Jun 01.
Article
en En
| MEDLINE
| ID: mdl-8676070
ABSTRACT
Many human tumor cells have been shown to express antigens that are recognized by autologous cytotoxic T lymphocytes (CTL) and the molecular nature of a number of melanoma antigens has been defined recently. Here we describe the characterization of an antigen recognized on a renal cell carcinoma by autologous CTL clones. This antigen is encoded by the HLA-A2 gene present in the tumor cells. The sequence of this gene differs from the HLA-A2 sequence found in autologous peripheral blood lymphocytes by a point mutation that results in an arginine to isoleucine exchange at residue 170, which is located on the alpha-helix of the alpha 2 domain. Transfection experiments with the normal and mutated HLA-A2 cDNA demonstrated that this amino acid replacement was responsible for the recognition of the HLA-A2 molecule expressed on the tumor cells. The mutant HLA-A2 gene was also detected in the original tumor tissue from the patient, excluding the possibility that the mutation had appeared in vitro. Thus, HLA class I molecules carrying a tumor-specific mutation can be involved in the recognition of tumor cells by autologous CTL.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Genes MHC Clase I
/
Carcinoma de Células Renales
/
Linfocitos T Citotóxicos
/
Antígeno HLA-A2
/
Mutación Puntual
/
Citotoxicidad Inmunológica
/
Neoplasias Renales
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Animals
/
Humans
Idioma:
En
Revista:
J Exp Med
Año:
1996
Tipo del documento:
Article
País de afiliación:
Bélgica